solid rais quarter increas price
reiter market outperform rate rais price target
share corpor follow
result ew report adjust sale mln mln mln
consensu mln bottom line compani report ep
ahead consensu estim
continu believ leadership posit transcathet
aortic valv replac tavr expertis transcathet valv bode well
compani benefit on-going expans sizabl market
abil becom major player sever emerg structur heart market
importantli view nascent transcathet mitral valv replac
tmvr repair tmvre market
base profil opportun see ahead continu believ
ew core hold large-cap med-tech growth investor
price target base ep vs previou
price target base prior ep
one-tim stock order germani
mln german hospit util mln inventori quarter
mln last quarter mln factor
underli sale respect quarter ep cite
adjust destock
guidanc unchang howev manag point
upper end guidanc rang set investor day decemb
due combin increas confid top line
favor tax chang ep expect rang vs
segment perspect everi categori came ahead expect
thv sale mln consensu mln surgic heart valv
sale mln consensu mln critic sale
transcathet valv sale mln increas driven strong
market growth manag believ roughli line ew
growth growth driven solid therapi adopt across
tavr center particularli strong growth lower-volum hospit
manag comment may final get better referr traction
transcathet valv sale increas underli cc basi
adjust german destock solid contribut across region
thomson reuter jmp secur llc
compani report jmp secur llc
report read conjunct import disclosur inform includ attest regul analyst certif
ce mark sapien ultra system expect quarter system featur advanc
design help tavr heart team simplifi procedur reduc risk complic
ultra system also add taller outer skirt valv design improv
 introduct sapien ultra system remain track late
ce mark expect centera month premium product price similar
sapien standard offer player
ew plan initi pivot trial centera
compani complet enrol main studi low-risk patient
sever aortic stenosi expect data trial present fda
approv like come later year
enrol continu early-tavr studi first-of-its-kind studi asymptomat
surgic heart valv valv receiv approv medicar new technolog add-on
payment went effect octob manag believ tailwind
add-on may help push global aortic surgic valv sale
addit inspiri resilia surgic valv see increas interest europ
recent launch valv featur compani long-last resilia tissu frame
specif design facilit futur valv valv tavr product present
favor altern younger patient may outliv tissu valv want deal
risk associ blood thin medic necessari mechan valv
ew began launch inspiri resilia last month januari
compani plan introduc inspiri resilia japan year pend reimburs
edward lifesci recent receiv ce mark harpoon recent acquir bleed heart
mitral valv repair system manag current focus integr activ expect
launch europ
critic busi ew expand launch hemospher compani next-
gener advanc monitor platform expect import growth driver
beyond hemospher design provid greater clariti patient hemodynam
statu enabl clinician make time potenti life-sav decis
quarter ew continu enrol patient activ trial cardioband
mitral posit compani alreadi ce mark product europ record revenu
mln thv categori ew began priorit suppli clinic
trial integr cardioband suppli chain qualiti system expect
creat headwind potenti growth product near term necessari step
manag continu expect revenu ramp mln full-year
compani complet enrol clasp ce mark trial pascal transcathet mitral
repair program manag encourag earli clinic experi reiter plan
edward lifesci track initi pascal trial
mitral side ew push forward transsept strategi make solid clinic
progress cardiaq sapien docking-st sapien platform
tricuspid repair compani receiv approv begin cardioband tricuspid early-
feasibl studi work activ center first half
tricuspid repair ce mark studi continu re-enrol manag believ track
begin introduct end
compani reiter top-lin guidanc laid analyst day decemb
point upper end rang company-wid sale segment base strong
perform head year increas expect favor tax chang
manag increas ep guidanc previous follow figur
lay key guidanc metric along select commentari
figur outlin result vs jmp estim rang revenu metric along select
thv bpsthv bpstotal bpssurgic heart bpscritic bpstotal mlnannual bpsgross bpsup y/i benefit higher mix tavr partial off-set cost associ plan closur swiss plant announc last bpsup y/i driven personnel-rel performance-bas compens well strengthen eur bpsup y/i primarili result continu invest transcathet structur heart program includ spend clinic trialsoper bpstax bpsnet bpsep ex adjust underli cc mln mln german stock order rever quarter underli growth solid across regionssolid growth across product portfolio notabl hospit utiiz year-end capit budgetssolid unit growth aortic driven larg intuiti elit benefit new technolog add-on payment went effect oct mix adjust german destockinggrowth line manag estim overal market growth quarter strong procedur growth driven robust adopt across tavr center particularli lower-volum hospit edward lifesci corpor ew
edward ew incom year mln except per share data total gross profit intellectu properti litig expens net- special charges- oper profit interest expens expens incom loss incom tax tax net incom ex oper ep ex analysisone-tim item one-tim net per oper ep ex net report basic share dilut share dividend per sale profit loss net chang y/i total profit loss net incom ex net ep ex ep ex amort outstand per edward lifesci corpor ew
edward lifesci corpor provid product technolog treat advanc cardiovascular diseas critic ill patient
world-wide compani offer heart valv therapi product includ tissu heart valv repair product util replac repair
patient diseas defect heart valv produc pericardi porcin valv biolog inert anim tissu sewn onto
proprietari wire form stent also provid critic care product compris hemodynam monitor system measur patient heart
function surgic intens care set addit compani offer cardiac surgeri system product manufactur
sell variou vascular product consist balloon-tip catheter-bas embolectomi product surgic clip clamp treat
endolumen occlus diseas compani distribut product direct sale forc independ distributor edward
lifesci corpor found headquart irvin california
bullish thesi ew revolv primarili around expans indic tavr market futur penetr tmvr market
addit smaller opportun pulmon tricuspid data may support on-going expans tavr market
uptak could take longer anticip tmvr opportun still infanc potenti sale fail materi
realiz market much smaller anticip on-going futur growth expect new arena may come fruition
addit med-tech heavili regul sector compani product candid may receiv approv expand indic
could meaning reduc futur revenu potenti
